The AstraZeneca share price dips as the company raises full-year guidance!

AstraZeneca’s biopharmaceutical business is delivering ongoing growth, so share price weakness now may be a buying opportunity.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Engineer Project Manager Talks With Scientist working on Computer

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The majority of City analysts rate AstraZeneca (LSE: AZN) as either a Buy or a Strong Buy, and there may be further long-term gains ahead for the share price.

Meanwhile, today’s (25 July) half-year report from the science-led biopharmaceutical company’s encouraging.

An upgrade to full-year guidance

In the first six months of 2024, constant currency revenue rose by 18% year on year. That filtered down to a 5% increase in core earnings per share over the period.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

Looking ahead, the directors are optimistic about the outlook and raised their guidance for the full year. They now expect total revenue and core earnings per share to grow by mid-teen percentages. Previously, the expectation was for low double-digit to low-teens percentages.

So it’s ongoing steady progress from the business after what has already been a long multi-year advance in revenues and earnings. The outcome for shareholders is clear in the share price chart — and it’s been good!

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

The company rewarded shareholders with an increase in the interim dividend of about 7.5%.

Chief executive Pascal Soriot is upbeat in the report saying the company has an ambition to hit $80bn of total annual revenue by 2030. To put that goal in perspective, the firm achieved just under $46bn in 2023, so it’s a stretching target.

However, the directors see “substantial” growth potential from approved medicines and those in the late-stage pipeline.

The year’s going well and AstraZeneca has already announced five “potentially practice-changing” Phase III studies. Soriot thinks they will “meaningfully” contribute to growth ahead.

Long-term growth potential

There’s been progress with several “disruptive” technologies and Soriot believes each has the potential to drive growth beyond 2030. For those with a technical mind, we’re talking about things such as antibody drug conjugates, bispecifics, cell & gene therapies, radioconjugates, and weight management medicines.  

It looks like the growth trajectory of the business is set to continue for some considerable time. So why is the share price weak today? As I type, its down almost 4% in early stock market trading.

This often happens on results day for companies, even if the news is good. Part of the reason might be investor expectations. If some shareholders anticipated an even better outlook statement than what has been delivered, they might have sold shares this morning.

After all, AstraZeneca stock’s staged a long, multi-year run higher, driven by increases in revenue and earnings. Part of the outcome is a valuation that looks ‘up with events’.

City analysts expect normalised earnings to increase by a triple-digit percentage this year and a further 15% in 2025. With the share price in the ballpark of 11,774p, the forward-looking price-to-earnings rating is just over 16 and the anticipated dividend yield is almost 2.2%.

One risk for shareholders is the company may not meet its growth expectations, perhaps because of disappointing outcomes from the research & development pipeline. If that happens, the share price may decline as the valuation adjusts lower.

However, despite the risks, the long-term growth forecast’s encouraging. I’d be inclined to use weakness in the share price as an opportunity to research the company as a potential long-term investment.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Growth stocks are crashing! Here’s what I’m doing now

Our writer shares his thoughts as growth stocks get crushed, as well as a favourite from the Nasdaq that he…

Read more »

Investing Articles

What’s going on with the Nvidia share price now?

The Nvidia share price is tanking. Once the most valuable listed company, Nvidia has seen more than $1trn wiped off…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 stocks that have been crushed and now offer a ton of value

Edward Sheldon has been scanning the market for stocks that offer value after the sell-off. Here are two shares he…

Read more »